Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Zynerba Pharmaceuticals	Strongbridge Biopharma	Heat Biologics	Antibe Therapeutics	Marker Therapeutics
Symbol	NASDAQ:ZYNE	NASDAQ:SBBP	NASDAQ:HTBX	OTCMKTS:ATBPF	NASDAQ:MRKR
Price Information
Current Price	$4.17	$2.42	$6.29	$3.54	$2.24
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.3	1.5	1.6	1.7	1.5
Analysis Score	3.4	3.5	3.5	3.5	3.4
Community Score	2.7	2.3	3.0	4.4	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	0.8	0.0	1.7
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$13.65	$7.50	$18.00	$7.95	$8.67
% Upside from Price Target	227.34% upside	209.92% upside	186.17% upside	124.58% upside	286.90% upside
Trade Information
Market Cap	$172.02 million	$163.46 million	$158.84 million	$161.42 million	$177.64 million
Beta	2.83	1.91	0.32	0.56	1.27
Average Volume	4,296,470	946,261	1,867,319	44,591	2,882,491
Sales & Book Value
Annual Revenue	$90,000.00	$21.71 million	$3.05 million	$7.51 million	$210,000.00
Price / Sales	1,911.34	7.53	52.08	21.49	845.90
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.26 per share	$1.33 per share	$2.73 per share	$0.10 per share	$0.96 per share
Price / Book	1.28	1.82	2.30	35.40	2.33
Profitability
Net Income	$-32,940,000.00	$-49,450,000.00	$-20,020,000.00	$-14,540,000.00	$-21,430,000.00
EPS	($1.50)	($1.10)	N/A	($0.50)	($0.47)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-149.79%	-527.90%	-273.96%	N/A
Return on Equity (ROE)	-60.20%	-65.85%	-44.07%	-150.49%	-68.00%
Return on Assets (ROA)	-52.40%	-38.81%	-36.38%	-98.51%	-54.26%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.10%	N/A	N/A	N/A
Current Ratio	6.54%	4.51%	31.34%	5.97%	5.03%
Quick Ratio	6.54%	4.45%	31.34%	5.42%	5.03%
Ownership Information
Institutional Ownership Percentage	25.99%	58.27%	49.84%	N/A	29.42%
Insider Ownership Percentage	11.10%	6.60%	5.50%	N/A	30.90%
Miscellaneous
Employees	26	72	39	47	44
Shares Outstanding	41.25 million	67.55 million	25.25 million	45.60 million	79.30 million
Next Earnings Date	N/A	5/12/2021 (Confirmed)	8/6/2021 (Estimated)	7/23/2021 (Estimated)	5/12/2021 (Confirmed)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Insiders are Buying These 3 Stocks - Should You? (MRKR) insidertrades.com - May 10 at 4:41 PM
	Marker Therapeutics, Inc. Forecasted to Post FY2022 Earnings of ($0.37) Per Share (NASDAQ:MRKR) americanbankingnews.com - May 9 at 3:36 AM
	Marker Recognizing Lynching in Columbia Vandalized usnews.com - May 8 at 2:19 PM
	Analysts Advise You To Build Your Position In Marker Therapeutics, Inc. (NASDAQ:MRKR) stocksregister.com - May 7 at 6:47 PM
	Analysts Set Expectations for Marker Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:MRKR) americanbankingnews.com - May 7 at 11:36 AM
	Marker Therapeutics (MRKR) Set to Announce Earnings on Wednesday americanbankingnews.com - May 5 at 7:34 AM
	Marker Therapeutics (MRKR) to Release Earnings on Wednesday americanbankingnews.com - May 5 at 7:34 AM
	Marker Therapeutics Inc. (NASDAQ:MRKR) surprises Wall Street with -4.48% stock price loss marketingsentinel.com - May 3 at 2:12 PM
	What lies ahead for Marker Therapeutics, Inc. (NASDAQ:MRKR) In 2020 stocksregister.com - April 30 at 8:15 AM
	Zacks: Analysts Anticipate Marker Therapeutics, Inc. (NASDAQ:MRKR) to Announce -$0.16 EPS americanbankingnews.com - April 29 at 10:34 PM
	Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 finance.yahoo.com - April 29 at 5:13 PM
	Thinking about buying stock in Hall of Fame Resort & Entertainment, Marker Therapeutics, LendingClub, Smith & Nephew, or Clover Health Investments? benzinga.com - April 29 at 12:11 PM
	Marker Therapeutics, Inc. (NASDAQ:MRKR): How Much Is It Worth And What Should Investors Do? marketingsentinel.com - April 29 at 12:11 PM
	'Historic Marker Day' targets maintenance of signs news.yahoo.com - April 28 at 10:46 AM
	‘Historic Marker Day’ targets maintenance of signs thedailynewsonline.com - April 28 at 5:46 AM
	Marker Therapeutics to Present Multi-Tumor-... benzinga.com - April 27 at 10:45 PM
	Analysts believe Marker Therapeutics, Inc. (NASDAQ:MRKR)’s share price will rise 214.96% from current levels stocksregister.com - April 27 at 12:44 PM
	Global Cardiac Marker Tests (In Vitro Diagnostics) Market Analysis and Forecast Model with COVID-19 Market Impact, 2015-2020 & 2020-2030 - ResearchAnd us.acrofan.com - April 26 at 4:39 PM
	Marker Therapeutics (NASDAQ:MRKR) & Xencor (NASDAQ:XNCR) Head-To-Head Contrast americanbankingnews.com - April 24 at 4:26 AM
	Market Analysts see Marker Therapeutics Inc. [MRKR] gaining to $6. Time to buy? dbtnews.com - April 23 at 1:17 AM
	Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Rating of "Buy" by Analysts americanbankingnews.com - April 22 at 2:34 AM
	Here’s Why Marker Therapeutics, Inc. (NASDAQ:MRKR) is an Attractive Pick for Investors Now stocksregister.com - April 20 at 2:50 PM
	Top 10 Best Bic Marker Sets 2021 bestgamingpro.com - April 20 at 9:49 AM
	Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Forecast for 2021: Bullish Signs Point to $8 per Share marketingsentinel.com - April 19 at 8:32 AM
	SDSU claims Dakota Marker title, top seed in FCS playoffs rapidcityjournal.com - April 18 at 5:09 PM

Date	Company	Brokerage	Action
5/6/2021	Zynerba Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
3/10/2021	Zynerba Pharmaceuticals	Roth Capital	Lower Price Target
2/5/2021	Zynerba Pharmaceuticals	Canaccord Genuity	Reiterated Rating
12/21/2020	Zynerba Pharmaceuticals	HC Wainwright	Lower Price Target
9/14/2020	Zynerba Pharmaceuticals	Needham & Company LLC	Reiterated Rating
6/29/2020	Zynerba Pharmaceuticals	LADENBURG THALM/SH SH	Reiterated Rating
9/16/2019	Zynerba Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
5/6/2020	Strongbridge Biopharma	Oppenheimer	Reiterated Rating
3/3/2020	Strongbridge Biopharma	Craig Hallum	Initiated Coverage
9/24/2019	Strongbridge Biopharma	Evercore ISI	Initiated Coverage
12/18/2018	Strongbridge Biopharma	Laidlaw	Initiated Coverage
8/9/2018	Strongbridge Biopharma	JMP Securities	Boost Price Target
8/8/2018	Strongbridge Biopharma	Janney Montgomery Scott	Boost Price Target
5/6/2021	Heat Biologics	Alliance Global Partners	Lower Price Target
2/9/2021	Heat Biologics	Maxim Group	Reiterated Rating
12/24/2020	Heat Biologics	B. Riley	Reiterated Rating
7/29/2019	Heat Biologics	Brookline Capital Management	Initiated Coverage
7/9/2018	Heat Biologics	Eurobank EFG	Initiated Coverage
9/4/2020	Antibe Therapeutics	Echelon Wealth Partners	Reiterated Rating
3/31/2021	Marker Therapeutics	Piper Sandler	Initiated Coverage
6/24/2020	Marker Therapeutics	Nomura	Reiterated Rating
11/13/2019	Marker Therapeutics	Piper Jaffray Companies	Lower Price Target
8/13/2019	Marker Therapeutics	Nomura Securities	Reiterated Rating
3/29/2019	Marker Therapeutics	WBB Securities	Upgrade

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources